Drug
Recaticimab
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_4
3
75%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 31 (25.0%)
Phase 43 (75.0%)
Trials by Status
not_yet_recruiting4100%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_4
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
NCT07674368
not_yet_recruitingphase_4
Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2×2 Randomized Controlled Trial
NCT07605130
not_yet_recruitingphase_4
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
NCT07290699
not_yet_recruitingphase_3
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis
NCT07119918
Clinical Trials (4)
Showing 4 of 4 trials
NCT07674368Phase 4
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
NCT07605130Phase 4
Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2×2 Randomized Controlled Trial
NCT07290699Phase 4
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
NCT07119918Phase 3
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4